Genomics stocks appear to be benefiting from AI, with the ARK Genomic Revolution ETF clearly outpacing broader biotech. x.com 

Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more

Genomics and innovation biotech stocks are an unusually asymmetric short: the companies are 50-100% overvalued even on an aggressive DCF and burn cash while rates break out. They are benefiting from quarter-end markups that end tomorrow, the chart is overbought, and they broke out on Moderna news that has nothing to do with them. Some will benefit from AI, but that is largely narrative. x.com 

ARKG's genomics thesis faces a timing problem, as much of the index consists of companies with no important clinical data readouts until 2028 or later. Clinical trials remain painstakingly long, and AI is moving faster than trial progress can keep up with, raising the question of when the broader biotech theme becomes overextended. x.com 

ARK Genomic Revolution ETF holds several of 2026's top-performing stocks as its biggest positions. The signal to take profits will be when CNBC features Cathie Wood on TV, likely within one to two months, since CNBC tends to ring the bell at the top. x.com 

Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Hims & Hers, Nautilus Biotechnology, Viking Therapeutics, Protagonist Therapeutics and Eli Lilly have 10x potential as peptide-related stocks; peptides will create generational wealth this year. Nautilus has a $230 million market cap, Viking $3.5 billion, Protagonist $9.1 billion and Lilly $1.1 trillion. x.com  x.com  x.com  x.com  x.com 

Nautilus Biotechnology is wildly overvalued at about $250M on just $190K of trailing-12-month revenue, a price richer than early-stage VC. That rebuts @alc2022's case that it owns the read layer for the proteome and could return 100-1,000x. x.com 

Zeta Global and Nautilus Biotechnology are two versions of the same idea, seeing deeper than anyone else: Zeta into the customer, Nautilus into the molecule. Both are aligned with something everyone wants, better information, and moved first to build the platforms that deliver it. Neither guarantees success, but both greatly raise the odds, which creates the asymmetry. Zeta is much further along in its zero-to-one journey. x.com